Search bioRxiv⌕ Search

Biology subjects

Brooks, N.

Publications and source records attributed to Brooks, N..

2 recordsLinked to original sources

Brain microvascular endothelial cell dysfunction during Plasmodium infection does not result from astrocyte-derived wingless-related integration site (Wnt)7a deficiency

Breakdown of the blood brain barrier is a key event leading to vasogenic edema that underpins pediatric cerebral malaria. Brain microvascular endothelial cells (BMECs) downregulate junction proteins in response to Plasmodium-infected red blood cells (iRBCs). Very little is known about how glial cell activation in Plasmodium infection dysregulates astrocyte-derived steady state signals that control BMEC junction expression. Astrocytes from mice infected with Plasmodium berghei ANKA (PbA) exhibit transcriptional changes dominated by interferon signaling pathways. Downregulation of wingless-related integration site (Wnt)7a transcription in astrocytes correlated with transcriptional changes in BMECs indicative of reduced {beta}-catenin activity. Incubation of the human astrocyte-like glioma cell-line CCF-STTG1 with interferon-{gamma} (IFN-{gamma}) decreased the general production of Wnt7a in response to P. falciparum iRBCs. However astrocyte conditioned medium incubated with IFN-{gamma} strengthened the barrier function in vitro when added onto monolayers the human cerebral microvascular endothelial cell line D3 (hCMEC/D3). This data suggests that the response of astrocytes during Plasmodium infection may be protective but unable to overcome dysfunctional responses of BMECs to Plasmodium iRBCs. To test this hypothesis we overexpressed Wnt7a in the brain tissue of mice using an AAV construct but this did not impart increased survival to the neurological effects of PbA infection. Therefore astrocyte responses during Plasmodium infection may not underlie the downregulation of junction proteins on BMECs leading to edema in cerebral malaria.

immunology↗

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer

Castration resistant prostate cancer (CRPC) remains an incurable disease stage with ineffective treatments options. Here, the androgen receptor (AR) coactivators CBP/p300, which are histone acetyltransferases, were identified as critical mediators of DNA damage repair (DDR) to potentially enhance therapeutic targeting of CRPC. Key findings demonstrate that CBP/p300 expression increases with disease progression and selects for poor prognosis in metastatic disease. CBP/p300 bromodomain inhibition enhances response to standard of care therapeutics. Functional studies, CBP/p300 cistrome mapping, and transcriptome in CRPC revealed that CBP/p300 regulates DDR. Further mechanistic investigation showed that CBP/p300 attenuation via therapeutic targeting and genomic knockdown decreases homologous recombination (HR) factors in vitro, in vivo, and in human prostate cancer (PCa) tumors ex vivo. Similarly, CBP/p300 expression in human prostate tissue correlates with HR factors. Lastly, targeting CBP/p300 impacts HR-mediate repair and patient outcome. Collectively, these studies identify CBP/p300 as drivers of PCa tumorigenesis and lay the groundwork to optimize therapeutic strategies for advanced PCa via CBP/p300 inhibition, potentially in combination with AR-directed and DDR therapies.

cancer biology↗